CN119139374A - A kind of preparation process of minoxidil mixed solution - Google Patents
A kind of preparation process of minoxidil mixed solution Download PDFInfo
- Publication number
- CN119139374A CN119139374A CN202411595954.1A CN202411595954A CN119139374A CN 119139374 A CN119139374 A CN 119139374A CN 202411595954 A CN202411595954 A CN 202411595954A CN 119139374 A CN119139374 A CN 119139374A
- Authority
- CN
- China
- Prior art keywords
- minoxidil
- ginsenoside
- mixed solution
- usma
- mass ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229960003632 minoxidil Drugs 0.000 title claims abstract description 85
- 239000011259 mixed solution Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 70
- 238000002156 mixing Methods 0.000 claims abstract description 41
- 239000000243 solution Substances 0.000 claims abstract description 41
- 239000012528 membrane Substances 0.000 claims abstract description 39
- 239000008367 deionised water Substances 0.000 claims abstract description 38
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 20
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 19
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 19
- 210000000130 stem cell Anatomy 0.000 claims abstract description 19
- 238000001035 drying Methods 0.000 claims abstract description 15
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 14
- 238000011068 loading method Methods 0.000 claims abstract description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 239000004744 fabric Substances 0.000 claims description 14
- 239000012046 mixed solvent Substances 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 11
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000012588 trypsin Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 210000003954 umbilical cord Anatomy 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 11
- 201000004384 Alopecia Diseases 0.000 abstract description 20
- 206010067484 Adverse reaction Diseases 0.000 abstract description 13
- 230000006838 adverse reaction Effects 0.000 abstract description 13
- 210000004761 scalp Anatomy 0.000 abstract description 11
- 201000002996 androgenic alopecia Diseases 0.000 abstract description 8
- 206010040844 Skin exfoliation Diseases 0.000 abstract description 7
- 230000035618 desquamation Effects 0.000 abstract description 7
- 208000010201 Exanthema Diseases 0.000 abstract description 6
- 201000005884 exanthem Diseases 0.000 abstract description 6
- 210000004209 hair Anatomy 0.000 abstract description 6
- 206010037844 rash Diseases 0.000 abstract description 6
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 230000007803 itching Effects 0.000 abstract description 5
- 206010068168 androgenetic alopecia Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 13
- 108010078791 Carrier Proteins Proteins 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 11
- 231100000360 alopecia Toxicity 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000001132 ultrasonic dispersion Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 241000227129 Aconitum Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000009583 hair follicle growth Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000501953 Aconitum pendulum Species 0.000 description 4
- 240000001592 Amaranthus caudatus Species 0.000 description 4
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 4
- 102000004257 Potassium Channel Human genes 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 235000012735 amaranth Nutrition 0.000 description 4
- 239000004178 amaranth Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 108020001213 potassium channel Proteins 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 150000003431 steroids Chemical group 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008195 breast development Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- -1 hair follicle growth Substances 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910000734 martensite Inorganic materials 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation process of minoxidil mixed solution, and relates to the technical field of pharmaceutical preparations. The invention discloses a minoxidil mixed solution, which is prepared by mixing soybean lecithin and ginsenoside and drying to obtain a phospholipid-ginsenoside membrane, wrapping minoxidil with the phospholipid-ginsenoside membrane to obtain minoxidil-ginsenoside transporter solution, extracting Wu Meadobe with deionized water to obtain an Wu Meadobe extract, loading the Wu Meadobe extract into human umbilical mesenchymal stem cells to obtain stem cell-loaded Wu Meadobe extract, and mixing minoxidil-ginsenoside transporter solution, stem cell-loaded Wu Meadobe extract and deionized water to obtain the minoxidil mixed solution. The minoxidil mixed solution prepared by the invention is used for treating androgenetic alopecia, has excellent treatment effect, and greatly reduces adverse reactions such as hair roughness, scalp itching, rash, desquamation and the like caused by single use of minoxidil.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a preparation process of minoxidil mixed solution.
Background
The problem of hair loss seriously affects the physiological and psychological health of people. The types of alopecia are various, and according to the current classification of clinical medicine, the types of alopecia can be generally classified into senile alopecia, chemotherapy alopecia, androgenetic alopecia, traction alopecia, alopecia areata, drug alopecia and scarring alopecia, and the incidence of androgenetic alopecia is the highest at present due to high mental stress or life style, and then alopecia areata is the next. Androgenic alopecia is a chronic progressive disease, and the incidence rate of men is greater than that of women in natural environments. Androgenetic alopecia is characterized by progressive miniaturization of hair follicles and thinning of hair shafts. Is a multifactorial disease caused by multifactorial interactions such as genes, androgens, age, and environment.
Minoxidil is an approved drug for treating hair loss by the U.S. food and drug administration, which can increase blood flow from skin blood to scalp by activating potassium channels, providing good blood flow to hair follicles and promoting hair follicle growth. However, minoxidil causes adverse reactions such as hair roughness, scalp itching, rash, desquamation, etc., and in order to reduce adverse reactions generated when a patient uses minoxidil, improvement of the therapeutic effect is necessary on the basis of the prior art.
Disclosure of Invention
The invention aims to provide a preparation process of minoxidil mixed solution, which aims to solve the problems in the prior art.
In order to solve the technical problems, the invention provides the following technical scheme:
A preparation process of minoxidil mixed solution comprises the steps of wrapping minoxidil with a phospholipid-ginsenoside membrane to obtain minoxidil-ginsenoside transporter solution, loading an Wu Meadobe extract into human umbilical cord mesenchymal stem cells to obtain a stem cell-carried Wu Meadobe extract, and mixing the minoxidil-ginsenoside transporter solution, the stem cell-carried Wu Meadobe extract and deionized water to obtain the minoxidil mixed solution;
The phospholipid-ginsenoside membrane is prepared by mixing soybean lecithin and ginsenoside and drying;
the Martensi karsch extract is prepared by extracting Martensi karsch with deionized water.
As optimization, the preparation process of the minoxidil mixed solution comprises the following preparation steps:
(1) Adding minoxidil and tween 80 into deionized water with the mass ratio of (0.12-0.13) being 8-10 times of that of minoxidil, stirring for 16-20 min at the temperature of 10-30 ℃ and the speed of 300-500 r/min, adding a phospholipid-ginsenoside membrane with the mass of 4-5 times of that of minoxidil, heating to 50-60 ℃, continuously stirring for 1-2 h, cooling to room temperature, standing for 1-2 h to obtain a carrier suspension, carrying out ultrasonic treatment on the carrier suspension at the temperature of 0-2 ℃ for 12-14 min, and filtering by a microporous filter membrane with the thickness of 0.22 mu m to obtain minoxidil-ginsenoside carrier solution;
(2) Mixing human umbilical mesenchymal stem cells, trypsin and PBS solution, performing ultrasonic dispersion for 2-3 min, placing into a centrifuge tube, centrifuging at 900r/min for 4-6 min to obtain a precipitate, namely a stem cell membrane, mixing the Martensi Temminck extract, the stem cell membrane and the PBS solution according to the mass ratio of 1 (3-4) (40-50), placing into the centrifuge tube, centrifuging at 900r/min for 7-8 min to obtain a stem cell-carried Martensi Temminck extract, and uniformly mixing the minoxidil-ginsenoside transporter solution, the stem cell-carried Martensi Temminck extract and deionized water to obtain a minoxidil mixed solution.
The preparation method of the phospholipid-ginsenoside membrane in the step (1) is optimized, wherein soybean lecithin and ginsenoside are added into a mixed solvent with the mass of 4-5 times of that of the soybean lecithin according to the mass ratio of 7:2, ultrasonic dispersion is carried out for 10-12 min at room temperature, and drying is carried out for 5-6 h at 20-30 ℃ under vacuum condition, so that the phospholipid-ginsenoside membrane is prepared.
The preparation method of the mixed solvent comprises the steps of uniformly mixing chloroform and methanol according to the mass ratio of 10:1 to prepare the mixed solvent.
The preparation method of the Wu-Ma-grass extract in the step (2) comprises the steps of uniformly mixing Wu-Ma-grass powder and deionized water according to the mass ratio of 1 (40-50), stirring for 2-3 hours at the temperature of 100 ℃ and 300-500 r/min, filtering with filter cloth, uniformly mixing filter residue and deionized water according to the mass ratio of 1 (20-24), stirring for 1 hour at the temperature of 100 ℃ and 300-500 r/min, filtering with filter cloth, mixing the two filtrates, centrifuging for 9-11 minutes at the temperature of 4500r/min, and drying supernatant at the temperature of 50-60 ℃ for 4-5 hours under the vacuum condition to obtain the Wu-Ma-grass extract.
Preferably, the Wu-Si-CAO powder is prepared by crushing Wu-Si-CAO into Wu-Si-CAO powder with particle size smaller than 3mm by using a wall breaking machine.
As optimization, the mass ratio of the human umbilical cord mesenchymal stem cells, trypsin and PBS solution in the step (2) is 1 (0.2-0.3) (80-100).
Preferably, the PBS solution in the step (2) is CD433577.
As optimization, the mass ratio of the minoxidil-ginsenoside transporter solution, the stem cell-carried Martensitic acid extract and deionized water in the step (2) is 1 (0.2-0.3) to 3-4.
Compared with the prior art, the invention has the following beneficial effects:
The invention relates to a preparation method of minoxidil mixed solution, which comprises the steps of mixing soybean lecithin and ginsenoside, drying to obtain a phospholipid-ginsenoside membrane, wrapping minoxidil with the phospholipid-ginsenoside membrane to obtain minoxidil-ginsenoside transporter solution, extracting Wu Meadobe with deionized water to obtain an Wu Meadobe extract, loading the Wu Meadobe extract into human umbilical mesenchymal stem cells to obtain stem cell-loaded Wu Meadobe extract, and mixing minoxidil-ginsenoside transporter solution, stem cell-loaded Wu Meadobe extract and deionized water.
Firstly, soybean lecithin and ginsenoside are mixed and dried to prepare a phospholipid-ginsenoside film, minoxidil is wrapped by the phospholipid-ginsenoside film to prepare minoxidil-ginsenoside transporter solution, and minoxidil is a medicament approved by the United states food and drug administration for treating alopecia, and can increase the blood flow of skin blood to scalp by activating potassium channels, so that good blood transport is provided for hair follicles to promote hair follicle growth. However, minoxidil causes adverse reactions such as hair roughness, scalp itching, rash, desquamation and the like, ginsenoside has anti-inflammatory effect and a steroid structure similar to cholesterol, has strong direct interaction with phospholipid and can be tightly inserted into a phospholipid bilayer, and minoxidil is entrapped in the ginsenoside, so that the transdermal absorption rate of minoxidil can be improved, the irritation of minoxidil to scalp is reduced, and the adverse reactions in use of minoxidil are reduced.
Secondly, extracting the Wu-Me grass with deionized water to obtain an Wu-Me grass extract; the method comprises the steps of loading the Ulmaria extract into human umbilical mesenchymal stem cells to prepare the stem cell-loaded Ulmaria extract, mixing minoxidil-ginsenoside transporter solution, the stem cell-loaded Ulmaria extract and deionized water to prepare minoxidil mixed solution, wherein the Ulmaria extract contains an inhibitory component of 5 alpha-reductase, which can convert testosterone into DHT with stronger activity and reduce DHT levels in blood and hair follicles by inhibiting testosterone, so that the microminiaturization of the hair follicles induced by DHT is relieved, the finasteride approved by the U.S. food and drug administration also has similar effects, but the finasteride can cause sexual dysfunction and psychological disorders, such as erectile dysfunction, hyposexuality, ejaculation dysfunction, breast development disorder, depression, headache, memory disorder and the like, so that the inhibitory component of 5 alpha-reductase extracted from natural plants can not only achieve the effect of treating androgenic alopecia, but also greatly reduce adverse reactions in the use process, and the use of the stem cell-loaded Ulmaria extract can improve the permeability of the Ulmaria extract, promote the growth factors, such as vascular growth factors, and the like, but also promote the growth of the growth factors, such as hair growth factor, hair follicle growth, growth factor, and the growth cycle, and the like.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1:
The preparation process of the minoxidil mixed solution comprises the following preparation steps:
(1) Uniformly mixing chloroform and methanol according to the mass ratio of 10:1 to prepare a mixed solvent, adding soybean lecithin and ginsenoside into the mixed solvent with the mass ratio of 7:2 and with the mass ratio of 4 times of the soybean lecithin, performing ultrasonic dispersion at room temperature for 10min, drying at 20 ℃ for 6h under vacuum condition to prepare a phospholipid-ginsenoside membrane, adding minoxidil and Tween 80 into deionized water with the mass ratio of 2:0.12 and with the mass ratio of 8 times of minoxidil, stirring for 20min at 10 ℃ and 300r/min, adding the phospholipid-ginsenoside membrane with the mass ratio of 4 times of minoxidil, heating to 50 ℃, continuously stirring for 2h, cooling to room temperature and standing for 1h to prepare a carrier suspension, performing ultrasonic treatment on the carrier suspension at 0 ℃ for 12min, and filtering with a microporous filter membrane with the mass ratio of 0.22 mu m to prepare a minoxidil-ginsenoside carrier solution;
(2) Crushing the Wu-Me grass into Wu-Me grass powder with the particle size smaller than 3mm by using a wall breaking machine, uniformly mixing the Wu-Me grass powder with deionized water according to the mass ratio of 1:40, stirring for 3h at 100 ℃ and 300r/min, filtering by using a filter cloth, uniformly mixing filter residues and deionized water according to the mass ratio of 1:20, stirring for 1h at 100 ℃ and 300r/min, filtering by using the filter cloth, mixing the two filtrates, centrifuging for 11min at 4500r/min, drying the supernatant at 50 ℃ for 5h under a vacuum condition to obtain an Wu-Me grass extract, mixing human umbilical mesenchymal stem cells, trypsin and PBS solution according to the mass ratio of 1:0.2:80, ultrasonically dispersing for 2min, placing into a centrifuge tube, centrifuging for 4min at 900r/min to obtain sediment, namely a stem cell membrane, mixing the Wu-Me grass extract, the stem cell membrane and PBS solution according to the mass ratio of 1:3:40, centrifuging for 7min at 900r/min, and uniformly mixing the Wu-Me-Mei-Bu grass extract and the Mei-bar extract with the mass ratio of 1:2.
Example 2:
The preparation process of the minoxidil mixed solution comprises the following preparation steps:
(1) Uniformly mixing chloroform and methanol according to the mass ratio of 10:1 to prepare a mixed solvent, adding soybean lecithin and ginsenoside into the mixed solvent with the mass ratio of 7:2 and the mass ratio of 4.5 times of the soybean lecithin, performing ultrasonic dispersion for 11min at room temperature, drying at 25 ℃ for 5.5h under vacuum condition to prepare a phospholipid-ginsenoside membrane, adding minoxidil and Tween 80 into deionized water with the mass ratio of 9 times of minoxidil according to the mass ratio of 2:0.125, stirring for 18min at 20 ℃ and 400r/min, adding the phospholipid-ginsenoside membrane with the mass ratio of 4.5 times of minoxidil, heating to 55 ℃, continuously stirring for 1.5h, cooling to room temperature, standing for 1.5h to prepare a transfersome suspension, performing ultrasonic dispersion for 13min at 1 ℃ and filtering by a microporous filter membrane with the mass ratio of 0.22 mu m to prepare a minoxidil-ginsenoside transfersome solution;
(2) Crushing the Wu-Me grass into Wu-Me grass powder with the particle size smaller than 3mm by using a wall breaking machine, uniformly mixing the Wu-Me grass powder with deionized water according to the mass ratio of 1:45, stirring for 2.5h at the temperature of 100 ℃ and 400r/min, filtering by using a filter cloth, uniformly mixing filter residues and deionized water according to the mass ratio of 1:22, stirring for 1h at the temperature of 100 ℃ and 400r/min, filtering by using the filter cloth, mixing the two filtrates, centrifuging for 10min at the temperature of 4500r/min, drying the supernatant at the temperature of 55 ℃ for 4.5h under the vacuum condition to obtain an Wu-Me grass extract, mixing human umbilical cord mesenchymal stem cells, trypsin and PBS (phosphate) solution according to the mass ratio of 1:0.25:90 for 2.5min, centrifuging for 5min at the mass ratio of 900r/min to obtain a precipitate, mixing the Wu-Me grass extract, the dry cell membrane and PBS (phosphate) solution according to the mass ratio of 1:3.5:45, centrifuging for 7.5min at the speed of 900r/min to obtain a centrifugal tube, uniformly dispersing the Wu-Me grass extract into a mixture of Meh.
Example 3:
The preparation process of the minoxidil mixed solution comprises the following preparation steps:
(1) Uniformly mixing chloroform and methanol according to the mass ratio of 10:1 to prepare a mixed solvent, adding soybean lecithin and ginsenoside into the mixed solvent with the mass ratio of 7:2 and with the mass ratio of 5 times of the soybean lecithin, performing ultrasonic dispersion at room temperature for 12min, drying at 30 ℃ for 5h under vacuum condition to prepare a phospholipid-ginsenoside membrane, adding minoxidil and Tween 80 into deionized water with the mass ratio of 2:0.13 and with the mass ratio of 10 times of minoxidil, stirring at 30 ℃ for 16min at 500r/min, adding the phospholipid-ginsenoside membrane with the mass ratio of 5 times of minoxidil, heating to 60 ℃, continuously stirring for 1h, cooling to room temperature, standing for 2h to prepare a carrier suspension, performing ultrasonic treatment on the carrier suspension at 2 ℃ for 14min, and performing filtration through a microporous filter membrane with the mass ratio of 0.22 mu m to prepare the minoxidil-ginsenoside carrier solution;
(2) Crushing the Wu-Me grass into Wu-Me grass powder with the particle size smaller than 3mm by using a wall breaking machine, uniformly mixing the Wu-Me grass powder with deionized water according to the mass ratio of 1:50, stirring for 2h at 100 ℃ and filtering with filter cloth, uniformly mixing filter residue and deionized water according to the mass ratio of 1:24, stirring for 1h at 100 ℃ and 500r/min, filtering with filter cloth, mixing the two filtrates, centrifuging for 11min at 4500r/min, drying the supernatant at 60 ℃ for 4h under vacuum condition to obtain an Wu-Me grass extract, mixing human umbilical mesenchymal stem cells, trypsin and PBS solution according to the mass ratio of 1:0.3:100, ultrasonically dispersing for 3min, placing into a centrifuge tube, centrifuging for 6min at 900r/min to obtain sediment, namely a stem cell membrane, centrifuging for 8min at 900r/min at a mass ratio of 1:4:50, and uniformly mixing the Wu-Me grass extract, the Hemsl extract and the PBS solution according to the mass ratio of 900r/min to obtain a Me-Me grass extract, and the Meh-Mei-Nuo extract solution.
Comparative example 1:
The preparation process of the minoxidil mixed solution of comparative example 1 is different from that of example 2 in that step (1) is not carried out, step (2) is modified in that the aconitum pendulum is broken into the aconitum pendulum powder with the particle size smaller than 3mm by a wall breaking machine, the aconitum pendulum powder and deionized water are uniformly mixed according to the mass ratio of 1:45, the mixture is stirred for 2.5h at 100 ℃ at 400r/min, filter cloth is filtered, filter residues and the deionized water are uniformly mixed according to the mass ratio of 1:22, the mixture is stirred for 1h at 100 ℃ at 400r/min, filter cloth is filtered, the two filtrates are mixed, the mixture is centrifuged for 10min at 4500r/min, the supernatant is dried for 4.5h under the vacuum condition, the mixture is dried for preparing the aconitum pendulum extract at 55 ℃, the mass ratio of 1:0.25:90 of human umbilical cord mesenchymal stem cells, trypsin and PBS solution is subjected to ultrasonic dispersion for 2.5min, the sediment is centrifuged for 5min at the speed of 900r/min, the sediment is the dry cell membrane is obtained, the filter membrane is obtained by centrifugation, the filter membrane is carried out at the speed of 1:5:5.5:5, the dry cell is carried by the centrifugation membrane, and the precipitation is carried by the centrifugation membrane is carried by the method of 1:1:0.5:0.5:7.5. The rest of the procedure is the same as in example 2.
Comparative example 2:
The preparation process of the minoxidil mixed solution of comparative example 2 is different from that of example 2 in that step (2) is not performed, step (1) is modified in that chloroform and methanol are uniformly mixed according to the mass ratio of 10:1 to prepare a mixed solvent, soybean lecithin and ginsenoside are added into the mixed solvent with the mass ratio of 4.5 times of that of the soybean lecithin according to the mass ratio of 7:2, ultrasonic dispersion is performed for 11min at room temperature, drying is performed for 5.5h at the temperature of 25 ℃ under the vacuum condition, a phospholipid-ginsenoside membrane is prepared, minoxidil and tween 80 are added into deionized water with the mass ratio of 9 times of minoxidil according to the mass ratio of 2:0.125, stirring is performed for 18min at 20 ℃ and 400r/min, the phospholipid-ginsenoside membrane with the mass ratio of 4.5 times of minoxidil is added, heating is performed to 55 ℃, stirring is continued for 1.5h, standing is performed for 1.5h after cooling to the room temperature, and the carrier suspension is prepared, the carrier suspension is subjected to ultrasonic dispersion for 13min at the temperature of 1 ℃, and the microporous filter membrane is subjected to micro-pore filtration to minoxidil filtration, so as to prepare the minoxidil mixed solution. The rest of the procedure is the same as in example 2.
Comparative example 3:
The minoxidil mixed solution of comparative example 3 is different from example 2 only in that the step (2) is modified in that the method comprises the steps of crushing the amaranth into amaranth powder with the particle size smaller than 3mm by a wall breaking machine, uniformly mixing the amaranth powder with deionized water according to the mass ratio of 1:45, stirring for 2.5h at 100 ℃, filtering by a filter cloth, uniformly mixing filter residues and deionized water according to the mass ratio of 1:22, stirring for 1h at 100 ℃, filtering by a filter cloth at 400r/min, mixing the two filtrates, centrifuging for 10min at 4500r/min, drying the supernatant at 55 ℃ for 4.5h under vacuum condition, and uniformly mixing minoxidil-ginsenoside transporter solution, the amaranth extract and the deionized water according to the mass ratio of 1:0.25:3.5 to obtain the minoxidil mixed solution. The rest of the procedure is the same as in example 2.
Test example 1
Test of androgenic alopecia treatment Property
The testing method comprises the following steps:
the method comprises the steps of taking 32 male mice with close weight, defining an area of 3cm multiplied by 3cm of the back of the mice as a test area, subcutaneously injecting testosterone propionate serving as an androgen into the mice in an amount of 5mg/kg each day, continuously injecting for 30 days, and observing that the hair in the injection area is obviously shed.
The 32 male mice were randomly divided into 8 groups of 4. Respectively, coating minoxidil mixed solution prepared in examples 1-3 and comparative examples 1-3 on mice in examples 1-3 and comparative examples 1-3, coating commercial Mi Luode mol solution on the positive control group, coating deionized water on the negative control group, each time 200 μl, and continuously administering once daily for 15 days to observe whether adverse reactions such as rash, desquamation, and red swelling appear in the hair growth of the test area of the mice.
After 15 days, all mice are sacrificed, the skin of the dehaired parts on the backs of the mice is taken, fixed with 4% paraformaldehyde for 24 hours, dehydrated, embedded in paraffin, sectioned, hematoxylin-stained for 5min, rinsed with tap water, the sections are dehydrated for 5min, eosin-stained for 5min, and the stained sections are observed under a common microscope. The hair follicle morphology was observed, the total number of hair follicles in each group was counted, and the average value was taken for each group. The results are shown in Table 1.
TABLE 1
| Group of | Whether or not adverse reaction occurs | Total number of hair follicles |
| Example 1 group | Without any means for | 92 |
| Example 2 group | Without any means for | 93 |
| Example 3 group | Without any means for | 91 |
| Comparative example 1 group | Slight redness and swelling | 76 |
| Comparative example 2 group | Without any means for | 75 |
| Comparative example 3 group | Without any means for | 82 |
| Positive control group | Obvious redness, swelling and desquamation | 59 |
| Negative control group | Without any means for | 34 |
From comparison of experimental data of the examples 1-3 and the comparative examples 1-3, the positive control group and the negative control group in Table 1, the minoxidil mixed solution prepared by the invention has excellent performance of treating androgenic alopecia.
By contrast, the groups 1-3 have no adverse reaction, the group 1 has slight adverse reaction, and the group 1 has obvious adverse reaction, which means that soybean lecithin and ginsenoside are mixed and dried to prepare a phospholipid-ginsenoside film, minoxidil is wrapped by the phospholipid-ginsenoside film to prepare minoxidil-ginsenoside transporter solution, minoxidil is a medicament approved by the food and drug administration in the United states for treating alopecia, the blood flow of skin blood to scalp can be increased by activating potassium channels, and good blood transport is provided for hair follicles to promote hair follicle growth. However, minoxidil causes adverse reactions such as hair roughness, scalp itching, rash, desquamation and the like, ginsenoside has anti-inflammatory effect and a steroid structure similar to cholesterol, has strong direct interaction with phospholipid and can be tightly inserted into a phospholipid bilayer, and minoxidil is entrapped in the ginsenoside, so that the transdermal absorbability of minoxidil can be improved, the irritation of minoxidil to scalp is reduced, and adverse reactions in use of minoxidil are reduced.
By contrast, the total number of hair follicles in examples 1-3 is greater than that in comparative examples 1-3, positive control group and negative control group, and it is shown that soybean lecithin and ginsenoside are mixed and dried to prepare a phospholipid-ginsenoside membrane, minoxidil is wrapped by the phospholipid-ginsenoside membrane to prepare minoxidil-ginsenoside transporter solution, minoxidil is a medicament approved by the U.S. food and drug administration for treating alopecia, and the blood flow of skin blood to scalp can be increased by activating potassium channels, so that hair follicles are provided with good blood transport and hair follicle growth promotion. However, minoxidil causes adverse reactions such as hair roughness, scalp itching, rash and desquamation, ginsenoside has an anti-inflammatory effect and a steroid structure similar to cholesterol, has strong direct interaction with phospholipid and can be tightly inserted into a phospholipid bilayer, minoxidil is entrapped in the ginsenoside to improve transdermal absorption rate of minoxidil, the method comprises the steps of extracting the minoxidil with deionized water to prepare an extract of the aconitum, loading the extract of the aconitum into human umbilical mesenchymal stem cells to prepare a stem cell-carrying-up extract of the aconitum, mixing minoxidil-carrying-up solution of the ginsenoside, the extract of the ginseng stem cell-carrying-up extract of the aconitum and the deionized water to prepare a minoxidil mixed solution, and the extract of the aconitum contains an inhibitory component of 5 alpha-reductase.
While the foregoing is directed to embodiments of the present invention, other and further details of the invention may be had by the present invention, it should be understood that the foregoing description is merely illustrative of the present invention and that no limitations are intended to the scope of the invention, except insofar as modifications, equivalents, improvements or modifications are within the spirit and principles of the invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411595954.1A CN119139374A (en) | 2024-11-11 | 2024-11-11 | A kind of preparation process of minoxidil mixed solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411595954.1A CN119139374A (en) | 2024-11-11 | 2024-11-11 | A kind of preparation process of minoxidil mixed solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119139374A true CN119139374A (en) | 2024-12-17 |
Family
ID=93809466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411595954.1A Pending CN119139374A (en) | 2024-11-11 | 2024-11-11 | A kind of preparation process of minoxidil mixed solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119139374A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2561858A2 (en) * | 2011-08-05 | 2013-02-27 | LABO Cosprophar AG | A composition for activating hair follicle stem cells to stimulate hair growth |
| CN105769911A (en) * | 2016-03-23 | 2016-07-20 | 中国人民解放军第二军医大学 | Hair regeneration method for mesenchymal stem cell-induced alopecia areata and application |
| CN106466299A (en) * | 2015-08-19 | 2017-03-01 | 上海本素医药科技有限公司 | Blank liposome with ginsenoside as membrane material, its preparation method and application |
| CN106659647A (en) * | 2014-06-30 | 2017-05-10 | 强生消费者公司 | Minoxidil-containing hair growth composition |
| KR101851388B1 (en) * | 2017-08-25 | 2018-06-07 | 주식회사 세화 피앤씨 | Composition for enhancing percutaneous absorption of ginsenosides, manufacturing method thereof and cosmetic preparations for hair growth |
| CN109010432A (en) * | 2018-10-18 | 2018-12-18 | 苏州工业园区服务外包职业学院 | A kind of Chinese and western medicinal composition of hair growth and its application |
| KR102082676B1 (en) * | 2018-12-27 | 2020-02-28 | 조형준 | Composition for hair care |
| CN111514178A (en) * | 2020-04-29 | 2020-08-11 | 刘应强 | Hair growth promoting medicine containing Uschma grass |
| CN115282214A (en) * | 2022-07-05 | 2022-11-04 | 广东橘国生物工程有限公司 | Preparation method for helping to activate stem cell function |
| CN116440145A (en) * | 2023-03-16 | 2023-07-18 | 西北大学 | Application of a kind of ginsenoside CK as a medicine for treating seborrheic alopecia |
-
2024
- 2024-11-11 CN CN202411595954.1A patent/CN119139374A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2561858A2 (en) * | 2011-08-05 | 2013-02-27 | LABO Cosprophar AG | A composition for activating hair follicle stem cells to stimulate hair growth |
| CN106659647A (en) * | 2014-06-30 | 2017-05-10 | 强生消费者公司 | Minoxidil-containing hair growth composition |
| CN106466299A (en) * | 2015-08-19 | 2017-03-01 | 上海本素医药科技有限公司 | Blank liposome with ginsenoside as membrane material, its preparation method and application |
| CN105769911A (en) * | 2016-03-23 | 2016-07-20 | 中国人民解放军第二军医大学 | Hair regeneration method for mesenchymal stem cell-induced alopecia areata and application |
| KR101851388B1 (en) * | 2017-08-25 | 2018-06-07 | 주식회사 세화 피앤씨 | Composition for enhancing percutaneous absorption of ginsenosides, manufacturing method thereof and cosmetic preparations for hair growth |
| CN109010432A (en) * | 2018-10-18 | 2018-12-18 | 苏州工业园区服务外包职业学院 | A kind of Chinese and western medicinal composition of hair growth and its application |
| KR102082676B1 (en) * | 2018-12-27 | 2020-02-28 | 조형준 | Composition for hair care |
| CN111514178A (en) * | 2020-04-29 | 2020-08-11 | 刘应强 | Hair growth promoting medicine containing Uschma grass |
| CN115282214A (en) * | 2022-07-05 | 2022-11-04 | 广东橘国生物工程有限公司 | Preparation method for helping to activate stem cell function |
| CN116440145A (en) * | 2023-03-16 | 2023-07-18 | 西北大学 | Application of a kind of ginsenoside CK as a medicine for treating seborrheic alopecia |
Non-Patent Citations (1)
| Title |
|---|
| 张菊芳等: "《现代毛发移植技术》", 31 May 2018, 浙江科学技术出版社, pages: 312 - 313 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108143669B (en) | Hair loss prevention and hair growth shampoo and preparation method thereof | |
| JP2021516701A (en) | Method for preparing composition for hair loss treatment | |
| CN119139374A (en) | A kind of preparation process of minoxidil mixed solution | |
| CN118834817B (en) | Preparation method of coptis exosome and application of coptis exosome in preparation of anti-ulcerative colitis medicines | |
| CN111870559B (en) | Liquid shampoo for preventing hair loss and growing hair and preparation method | |
| CN108403549A (en) | A cleansing mousse containing fullerene | |
| CN111228330A (en) | Stephanine-containing anti-inflammatory pharmaceutical composition and preparation method thereof | |
| CN111150056A (en) | Noni peptide enzyme and preparation method and application thereof | |
| CN109700830A (en) | A kind for the treatment of gastritis and the drug of peptic ulcer in good taste and preparation method thereof | |
| CN114573725A (en) | Extraction method of spina date seed polysaccharide extract | |
| CN112675068A (en) | Preparation method of face cream of autologous adipose-derived stem cell cytokine extracting solution | |
| CN109971813A (en) | A kind of technique preparing bisnoralchol | |
| TWI875548B (en) | Use of fermentation broth of salvia miltiorrhiza for manufacturing agent to promote hair growth | |
| CN118593375B (en) | A fermentation anti-hair loss composition and preparation method thereof | |
| CN114480152A (en) | Preparation method and application of vitronectin-containing yeast fermentation product filtrate composition | |
| WO2022242563A1 (en) | Pharmaceutical use of cdk4/6 inhibitor | |
| CN103006716A (en) | Hypocrellin external preparation for treating leucoderma | |
| CN118477039B (en) | Use of toad oil cream in preparing medicine for treating dermatitis | |
| CN119157251A (en) | A composition for warming and tonifying kidney yang and enhancing immunity, and its preparation method and application | |
| CN107375142A (en) | A kind of preparation method of Chinese medicine beauty antiwrinkle cream | |
| CN119345063A (en) | A redness-removing and allergy-relieving medical recombinant collagen repair patch and its preparation method | |
| CN119792366A (en) | Exosome compound for promoting hair growth, hair growth liquid and application thereof | |
| CN119097700A (en) | Pharmaceutical composition containing Pt@PCN-Cu and PD-L1 antibody and its application in tumor treatment | |
| TW202247853A (en) | Use of extract of barley malt | |
| CN119818616A (en) | Hair-loss-stopping hair-growing composition based on biota orientalis compound extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |